Clinical trials have shown that the combination of everolimus, trastuzumab, and paclitaxel can improve progression-free survival (PFS) in patients with hormone receptor (HR)-negative and HER2-positive advanced BC [9]. The gene discussed is ERBB2; the disease is breast cancer.